Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis
Table 2
Patient baseline demographic and clinical characteristics (matched).
Characteristics
cTACE ()
cTACE+HAIC ()
value
Standardized mean difference
Age (years)†
0.510
0.036
Sex
0.789
0.099
Male
51 (85.0)
53 (88.3)
Female
9 (15.0)
7 (11.7)
Etiology
0.714
0.061
Hepatitis B virus
54 (90.0)
53 (88.3)
Hepatitis C virus
3 (5.0)
3 (5.0)
Unknown/other
3 (5.0)
4 (6.7)
Cirrhosis clinical course
Stage 1-2
54 (90.0)
49 (81.7)
0.295
Stage 3-4
6 (10.0)
11 (18.3)
Child-Pugh class
1.000
0.000
A
56 (93.3)
56 (93.3)
B
4 (6.7)
4 (6.7)
ALB grade
0.163
0
58 (96.7)
53 (88.3)
1-2
2 (3.3)
7 (11.7)
ECOG performance status
1.000
0.000
0
36 (60.0)
36 (60.0)
1-2
24 (40.0)
24 (40.0)
Portal vein invasion stage
0.138
0.000
Vp1-2
8 (13.3)
3 (5.0)
Vp3
28 (46.7)
38 (63.3)
Vp4
24 (40.0)
19 (31.7)
Extrahepatic spread
0.709
0.069
Absent
35 (58.3)
37 (61.7)
Present
25 (41.7)
23 (38.3)
Tumor diameter (mm)
0.852
0.068
>100
25 (41.7)
23 (38.3)
≤100
35 (58.3)
37 (61.7)
(mm)†
0.747
AFP (ng/mL)‡
3000 ()
4808 ()
0.282
0.000
≤1000
26 (43.3)
26 (43.3)
1.000
>1000
34 (56.6)
34 (56.6)
ALB: albumin; TACE: transcatheter arterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy; AFP: serum α-fetoprotein level; SD: standard deviation. †Data .‡Data were median (full range). Unless indicated otherwise, data are the number of patients, with percentages in parentheses. Continuous variables were analyzed using the two-sample test, or the Wilcoxon rank-sum test was used. Categorical variables were compared by using the test.
